Stock Movers

- Intel (INTC) shares fell Wednesday after a report said that Nvidia Corp. halted a test to use Intel’s production process to make advanced chips. Nvidia recently tested the so-called 18A process but stopped moving forward, Reuters reported, citing two unidentified people familiar with the matter. Spokespeople for Nvidia and Intel didn’t immediately respond to requests for comment. An Intel spokesperson told Reuters that the company’s 18A manufacturing technologies are “progressing well.” - Dynavax (DVAX) soared after Sanofi agreed to buy the small biopharmaceutical firm for about $2.2 billion, as it seeks to expand a vaccines business currently anchored by its flu shot franchise. The French drugmaker will pay $15.50 a share in cash for Dynavax, 39% above the Emeryville, California-based firm’s closing price Tuesday. The statement on Wednesday came minutes after Sanofi said the US Food and Drug Administration had surprisingly rejected its experimental multiple sclerosis drug tolebrutinib. - Snowflake (SNOW) dipped after The Information reported that the software company is in talks to buy the closely held Observe Inc. for around $1 billion. Baird writes that such a deal “could make strategic sense” as a way to compete with Databricks, which “has been very acquisitive to expand its platform.”See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:- Shares of Intel (INTC) fell in the early session after Reuters reported that Nvidia halted a test that uses the chip manufacturer’s 18A technology to produce its chips. Nvidia recently tested whether it could manufacture its chips using Intel’s 18A production process but stopped moving forward, Reuters reported, citing two people familiar with the matter. Nvidia did not respond to Reuters’ request for comment, while an Intel spokesperson told Reuters the company’s 18A manufacturing technologies are “progressing well.”- Shares of Dynavax Technologies (DVAX) soared in premarket trading after Sanofi agreed to buy Dynavax for about $2.2 billion, as it seeks to expand a vaccines business currently anchored by its flu shot franchise. The French drugmaker will pay $15.50 a share in cash for Dynavax, 39% above the Emeryville, California-based firm’s closing price Tuesday. The statement on Wednesday came minutes after Sanofi said the US Food and Drug Administration had surprisingly rejected its experimental multiple sclerosis drug tolebrutinib.- Shares of Nike (NKE) moved higher ahead of the US market open after a filing shows that Apple CEO Tim Cook purchased $2.95 million worth of shares on December 22nd. Cook is Nike’s lead independent director and served as a director since 2005, according to the company’s website.See omnystudio.com/listener for privacy information.

On This episode of Stock Movers:- BP agreed to sell a majority stake in its Castrol lubricants division to US investment firm Stonepeak Partners to raise about $6 billion.- French biotech company Abivax started the year with a market value of less than $500 million. After a meteoric rally, it’s now worth more than $8 billion — and some analysts see the potential for even more gains- B&M's stock has fallen 56% in 2025, extending the previous year’s 34% drop, as the firm struggles to contend with a cocktail of rising competition, increasing wage costs and a pinch on the low-income households that have been key to its past success.See omnystudio.com/listener for privacy information.

On This episode of Stock Movers:- BP Plc agreed to sell a majority stake in its Castrol lubricants division to US investment firm Stonepeak Partners to raise about $6 billion.- Sanofi agreed to buy Dynavax Technologies Corp. for about $2.2 billion, as the French drugmaker tries to expand a vaccines business currently anchored by its flu shot franchise.- Fresnillo and other european mining stocks may be active on Wednesday as gold rises above $4,500 an ounce for the first time on escalating tensions in Venezuela and expectations for more US interest rate cuts. Silver, platinum and copper also hit recordsSee omnystudio.com/listener for privacy information.

On this episode of Stock Movers:- Novo Nordisk (NVO) shares rallied in trading today following the drugmaker getting US approval to sell a pill version of its blockbuster obesity shot Wegovy. Novo will start selling the pill in the US in early January, the company said in a statement Monday. It is approved to help people lose weight or maintain previous weight loss over the long term. The pill is crucial for Novo’s strategy to take on Eli Lilly, which has said its own oral obesity drug could be approved by March. That would give Novo a head start of just a few months. - ServiceNow (NOW) has reached a deal to buy the cybersecurity startup Armis in a deal valued at $7.75 billion, representing its largest acquisition to date. The Santa Clara, California-based enterprise tech company will pay in cash for San Francisco-based Armis, according to a statement Tuesday that confirmed an earlier Bloomberg News report. ServiceNow, which provides software that helps companies organize and automate their personnel and information technology operations, has become a dominant platform for enterprise workflow. In March, ServiceNow struck an agreement to buy the artificial intelligence firm Moveworks Inc. for $2.85 billion as part of its push into AI tools that can complete tasks without human supervision. Shares of the startup fell during trading on Tuesday.- Sable (SOC) shares rose as much as 30% after the company said that the US Department of Transportation, Pipeline and Hazardous Materials Safety Administration approved the firm’s Las Flores pipeline restart plan.See omnystudio.com/listener for privacy information.